SANTA
MONICA, Calif., April 29,
2022 /PRNewswire/ -- Opiant Pharmaceuticals
(NASDAQ: OPNT) was the subject of a fake news release issued on
Friday, April 29, 2022, that falsely
stated Opiant announced a partnership with
Hikma Pharmaceuticals, PLC.
Opiant had no knowledge of the press release issued by Cision PR
Newswire, and it is fake. Opiant and Hikma are not involved in
any discussions of this type.
Cision PR Newswire issued a notice across its service confirming
that journalists, investors and other readers should disregard the
news release, "Opiant Pharmaceuticals and Hikma announce exclusive
$225 million commercialisation and
license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK" issued April 29, 2022, over Cision PR
Newswire.
All further questions should be directed to Cision PR
Newswire.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
View original
content:https://www.prnewswire.com/news-releases/opiant-pharmaceuticals-issues-statement-in-response-to-fake-press-release-301536458.html
SOURCE Opiant Pharmaceuticals, Inc